Toxicological and Pharmacological Use of Anticancer Compounds

  • Charles Gnanaraj
  • Sivapragasam Gothai
  • Katyakyini Muniandy
  • Rengarajan Thamaraiselvan
  • Palanisamy Arulselvan


Knowledge of medicinal plants from traditional medicinal drug therapy has brought limitless implications towards the discovery of novel compounds for modern therapeutic applications particularly for anticancer research. Research approaches have been taken for the development of traditional medicinal products into effective, non-toxic and clinically proven pharmaceuticals. Plant-derived anticancer compounds might exert adverse toxic effects in humans, depending on the species of plant, drug administration route, dose regimens and drug receptiveness. Due to this possibility, it is important to assess the toxicity profiles of new potential anticancer compounds through proper toxicological tests. The importance of preclinical toxicology studies is continually drifting from the use of conventional methods to assess the impending adverse effects of new anticancer agents over the past 10 years. Recent practice encompasses designing and carrying out more personalized agent-directed research within the framework of clinical pharmacology guidelines. Distinctive standpoints have been brought into view by clinical application of anticancer drugs that are apparent in their discovery and development. Evolving standards in estimating novel drug candidates through clinical and preclinical trials manifest the cytotoxic compound enhancements over time, with substantial aid from circumstances, and the current interest in discovering drug candidates with specifications on reaching targeted cells. This chapter highlights the relevance of plant-derived anticancer compounds through their pharmacological and toxicological uses.


Anticancer compounds Clinical pharmacology Drug discovery Toxicity Polyphenols 


  1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. JNCI: Journal of the National Cancer Institute 102(1):14–25CrossRefPubMedPubMedCentralGoogle Scholar
  2. Alkhalfioui F, Magnin T, Wagner R (2009) From purified GPCRs to drug discovery: the promise of protein-based methodologies. Curr Opin Pharmacol 9:629–635CrossRefPubMedGoogle Scholar
  3. Almeida DA, Piazza JR, Stawski RS (2009) Inter-individual differences and intra-individual variability in the cortisol awakening response: an examination of age and gender. Psychol Aging 24:819–827CrossRefPubMedPubMedCentralGoogle Scholar
  4. Alqahtani S, Mohamed LA, Kaddoumi A (2013) Experimental models for predicting drug absorption and metabolism. Expert Opin Drug Metab Toxicol 9:1241–1254CrossRefPubMedGoogle Scholar
  5. Alsarhan A, Sultana M, Khatib AA, Kadir MRA (2014) Review on some Malaysian traditional medicinal plants with therapeutic properties. J Basic Appl Sci 10:149–159CrossRefGoogle Scholar
  6. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM, Spandidos DA (2010) Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 126:9–20CrossRefPubMedGoogle Scholar
  7. Arber A, Odelius A, Williams P, Lemanska A, Faithfull S (2017) Do patients on oral chemotherapy have sufficient knowledge for optimal adherence. A mixed methods study. Eur J Can Care 26:e12413CrossRefGoogle Scholar
  8. Arulselvan P, Fard MT, Tan WS, Gothai S, Fakurazi S, Norhaizan ME, Kumar SS (2016a) Role of antioxidants and natural products in inflammation. Oxidative Med Cell Longev 2016:5276130CrossRefGoogle Scholar
  9. Arulselvan P, Tan WS, Gothai S, Muniandy K, Fakurazi S, Esa NM, Alarfaj AA, Kumar SS (2016b) Anti-inflammatory potential of ethyl acetate fraction of Moringa oleifera in downregulating the NF-kB signaling pathway in lipopolysaccharide-stimulated macrophages. Molecules 21:E1452CrossRefPubMedGoogle Scholar
  10. Arzamastseva N, Lapina Y, Ageev F, Lankin V, Mareev V, Belenkov Y (2007) Influence of metformin on the parameters of oxidative stress in patients with combined heart failure and diabetes mellitus. Eur J Heart Fail Suppl 6:123–134CrossRefGoogle Scholar
  11. Atanas GA, Birgit W, Eva-Maria PW, Thomas L, Christoph W, Pavel U, Eronika T, Limei W, Stefan S, Ele H (2015) Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv 33:1582–1614CrossRefGoogle Scholar
  12. Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP (2013) Honokiol: a non-adipogenic PPAR gamma agonist from nature. Biochim Biophys Acta 1830:4813–4819CrossRefPubMedPubMedCentralGoogle Scholar
  13. Aung TN, Qu Z, Kortschak RD, Adelson DL (2017) Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci 18:1–20CrossRefGoogle Scholar
  14. Ayoola GA (2008) Phytochemical screening and antioxidant activities of some selected medicinal plants used for malaria therapy in southwestern Nigeria. Trop J Pharm Res 7:1019–1024Google Scholar
  15. Bao Y, Fenwick R (2004) Phytochemicals in health and disease. CRC Press, New YorkCrossRefGoogle Scholar
  16. Berkov S, Bastida NM, Viladomat CC (2008) Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts. Phytochem Anal 19:411–419CrossRefPubMedGoogle Scholar
  17. Bishayee A, Ahmed S, Brankov N, Perloff M (2011) Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 16:980–996CrossRefPubMedCentralGoogle Scholar
  18. Borkova L, Adamek R, Kalina P, Drasar P, Dzubak P, Gurska S, Rehulka J, Hajduch M, Urban M, Sarek J (2017) Synthesis and cytotoxic activity of triterpenoid thiazoles derived from allobetulin, methyl betulonate, methyl oleanonate, and oleanonic acid. Chem Med Chem 12:390–398CrossRefPubMedGoogle Scholar
  19. Botha CJ, Penrith ML (2008) Poisonous plants of veterinary and human importance in southern Africa. J Ethnopharmacol 119:549–558CrossRefPubMedGoogle Scholar
  20. Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67:2141–2153CrossRefPubMedGoogle Scholar
  21. Chanda S, Dave R (2009) In-vitro models for antioxidant activity evaluation and some medicinal plants possessing antioxidant properties: an overview. Afr J Microbiol Res 3:981–996Google Scholar
  22. Chudzik M, Szlacheta IK, Krol W (2015) Triterpenes as potentially cytotoxic compounds. Molecules 20:1610–1625CrossRefPubMedGoogle Scholar
  23. Chun TC, Zhi JW, Moses SC, Christopher WL (2011) Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules 18:5125–5141Google Scholar
  24. Colomer R, Alba E, González-Martin A, Paz-Ares L, Martin M, Llombart A, Lescure AR, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germa JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J (2010) Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol 21:195–198CrossRefPubMedPubMedCentralGoogle Scholar
  25. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB (2004) Oxidative stress, redox and tumor micro environment. Semin Radiat Oncol 14:256–266CrossRefGoogle Scholar
  26. Cragg GM, Newman DJ (2004) A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 67:232–244CrossRefPubMedGoogle Scholar
  27. Cragg GM, Newman DJ (2005) Plants as sources of anticancer agents. J Ethnopharmacol 100:72–79CrossRefGoogle Scholar
  28. Cyriac JM, James E (2014) Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother 5:83–87CrossRefPubMedPubMedCentralGoogle Scholar
  29. Demain AL, Vaishnav P (2011) Natural products for cancer chemotherapy. Microb Biotechnol 4:687–699CrossRefPubMedPubMedCentralGoogle Scholar
  30. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692CrossRefPubMedGoogle Scholar
  31. Francis G, Kerem Z, Makkar HPS, Becker K (2002) The biological action of saponins in animal systems: a review. Brit J Nut 88:587–605CrossRefGoogle Scholar
  32. Gnanaraj C, Shah MD, Makki JS, Iqbal M (2016) Hepatoprotective effects of Flagellaria indica L. are mediated through the suppression of pro-inflammatory cytokines and oxidative stress markers in rats. Pharm Biol 54:1420–1433CrossRefPubMedGoogle Scholar
  33. Godugu C, Patel AR, Doddapaneni R, Somagoni J, Singh M (2014) Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One 9:e89919CrossRefPubMedPubMedCentralGoogle Scholar
  34. Gonzalo JD (2011) Toxic plants of veterinary and agricultural interest in Colombia. Int J Poison Plant Res 1:1–15Google Scholar
  35. Gordaliza M, Garcia PA, Del Corral JM, Castro MA, Gomez-Zurita MA (2004) Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 44:441–459CrossRefPubMedGoogle Scholar
  36. Gothai S, Ganesan P, Park SY, Fakurazi S, Choi DK, Arulselvan P (2016) Natural phyto-bioactive compounds for the treatment of type 2 diabetes: inflammation as a target. Nutrition 8:E461Google Scholar
  37. Grunwald HW (2007) Ethical and design issues of phase I clinical trials in cancer patients. Cancer Investig 25:124–126CrossRefGoogle Scholar
  38. Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Pfrenkel U, Becerra CR (2006) Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin 27:1375–1381CrossRefPubMedGoogle Scholar
  39. Halket JM, Daniel W, Anna MP, Raj KP, Paul DF, Peter MB (2005) Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS. J Exp Bot 56:219–243CrossRefPubMedGoogle Scholar
  40. Hamid N, Hedayatollah S (2013) Toxicity and safety of medicinal plants. J Herb Med Pharmacol 2:21–22Google Scholar
  41. Hassanzadeh P (2011) Colorectal cancer and NF-kB signalling pathway. Gasteroenterol Hepatol 4:127–132Google Scholar
  42. He X, Clarke SJ, McLachlan AJ (2011) Clinical pharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriat Res 2011:628670CrossRefGoogle Scholar
  43. Jantan I, Ahmad W, Bukhari SNA (2015) Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front Plant Sci 6:655CrossRefPubMedPubMedCentralGoogle Scholar
  44. Jeffrey S, Michal B (2009) A combined evolution/structure-based approach to protein function prediction. Brief Bioinform 2:1–14Google Scholar
  45. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev 4:253–265CrossRefGoogle Scholar
  46. Kawaguchi H, Hirakawa K, Miyauchi K, Koike K, Ohno Y, Sakamoto A (2010) Pattern recognition analysis of proton nuclear magnetic resonance spectra of brain tissue extracts from rats anesthetized with propofol or isoflurane. PLoS One 5:e11172CrossRefPubMedPubMedCentralGoogle Scholar
  47. Kingston GI (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72:507–515CrossRefPubMedPubMedCentralGoogle Scholar
  48. Klekota J, Brauner E, Roth FP, Schreiber SL (2006) Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects. J Chem Inf Model 46:1549CrossRefPubMedGoogle Scholar
  49. Kyselova Z (2011) Toxicological aspects of the use of phenolic compounds in disease prevention. Interdiscip Toxicol 4:173–183CrossRefPubMedPubMedCentralGoogle Scholar
  50. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ (2012) Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Pharm Chem 55:4527–4538CrossRefGoogle Scholar
  51. Leeuwen RWF, Brundel DHS, Gelder TV, Mathijssen RHJ, Burger DM, Jansman FGA (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Brit J Can 108:1071–1078CrossRefGoogle Scholar
  52. Leonard IZ, Randall TP (2005) In vivo drug discovery in the zebra fish. Nat Rev Drug Discov 4:35–44CrossRefPubMedGoogle Scholar
  53. Luc P, Arnold JV (2005) Bio-guided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds. J Ethnopharmacol 100:57–60CrossRefGoogle Scholar
  54. Marcy JB, Douglas KB (2005) Drug discovery from medicinal plants. Life Sci 78:431–441CrossRefGoogle Scholar
  55. Mathijssen RHJ, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272–281CrossRefPubMedGoogle Scholar
  56. Millimouno FM, Dong J, Yang L, Li J, Li X (2014) Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res 7:1081–1107CrossRefGoogle Scholar
  57. Ming-Wei W, Xiaojiang H, Kaixian C (2007) Biological screening of natural products and drug innovation in China. Phil Trans Royal Soc B 362:1093–1105CrossRefGoogle Scholar
  58. Mishra BB, Tiwari VK (2011) Natural products: an evolving role in future drug discovery. Eur J Med Chem 46:4769–4807CrossRefPubMedGoogle Scholar
  59. Mondal J, Panigrahi AK, Khuda-Bukhsh AR (2014) Conventional chemotherapy: problems and scope for combined therapies with certain herbal products and dietary supplements. Aus J Mol Cell Biol 1:10Google Scholar
  60. Montellano PROD (2013) Cytochrome P450-activated prodrugs. Future Med Chem 5:213–228CrossRefGoogle Scholar
  61. Moudi MGR, Yien CYS, Nazre M (2013) Vinca alkaloids. Int J Prev Med 4:1231–1235PubMedPubMedCentralGoogle Scholar
  62. Mullauer FB, Kessler JH, Madema JP (2010) Betulinic acid, a natural compound with potent anti-cancer effects. Anti-Can Drugs 21:215–227CrossRefGoogle Scholar
  63. Mut-Salud N, Alvarez PJ, Garrido JM, Carrasco E, Aranega A, Rodriguez-Serano F (2016) Antioxidant intake and antitumor therapy: toward nutritional recommendations for optimal results. Oxidative Med Cell Longev 2016:6719534CrossRefGoogle Scholar
  64. Nair MP, Mahajan S, Reynolds JL, Aalinkeel R, Nair H, Schwartz SA, Kandaswami C (2006) The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor-alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kβ system. Clin Vaccine Immunol 13:319–328CrossRefPubMedPubMedCentralGoogle Scholar
  65. Narang AS, Desai DS (2009) Anticancer drug development: unique aspects of pharmaceutical development. In: Lu Y, Mahato RI (eds) Pharmaceutical perspectives of cancer therapeutics. Bristol-Myers Squibb, New Brunswick, pp 49–92CrossRefGoogle Scholar
  66. Nassiri AM, Hosseinzadeh H (2008) Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 22:709–724CrossRefGoogle Scholar
  67. Ndhlala AR, Ncube B, Okem A, Mulaudzi RB, Staden JV (2013) Toxicology of some important medicinal plants in southern Africa. Food Chem Toxicol 62:609–621CrossRefPubMedGoogle Scholar
  68. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335CrossRefPubMedPubMedCentralGoogle Scholar
  69. Nonnekens J, Hoeijmakers JHJ (2017) After surviving cancer, what about late life effects of the cure. EMBO Mol Med 9:4–6CrossRefPubMedGoogle Scholar
  70. Parasuram S (2011) Toxicological screening. J Pharmacol Pharmacother 2:74–79CrossRefGoogle Scholar
  71. Park EJ, Pezzuto JM (2002) Botanicals in cancer chemoprevention. Can Met Rev 21:231–255CrossRefGoogle Scholar
  72. Park JY, Park CM, Kim JJ, Noh KH, Cho CW, Song YS (2007) The protective effect of chlorophyll against oxidative stress and inflammatory processes in LPS-stimulated macrophages. Food Sci Biotechnol 16:205–211Google Scholar
  73. Petronelli A, Pannitteri G, Testa U (2009) Triterpenoids as new promising anticancer drugs. Anti-Can Drugs 20:880–892CrossRefGoogle Scholar
  74. Philomena G (2011) Concerns regarding the safety and toxicity of medicinal plants-an overview. J App Pharm Sci 1:40–44Google Scholar
  75. Ponmari G, Annamalai A, Gopalakrishnan VK, Lakshmi PTV, Guruvayoorappan C (2014) NF-kB activation and proinflammatory cytokines mediated protective effect of Indigofera caerulea Roxb. on CCl4 induced liver damage in rats. Int Immunopharmacol 23:672–680CrossRefPubMedGoogle Scholar
  76. Qiu S, Sun H, Zhang AH, Xu HY, Yan GL, Han Y et al (2014) Natural alkaloids: basic aspects, biological roles, and future perspectives. Chin J Nat Med 12:401–406PubMedGoogle Scholar
  77. Rabi T, Bishayee A (2009) Terpenoids and breast cancer prevention. Breast Cancer Res Treat 115:223–239CrossRefPubMedGoogle Scholar
  78. Rasoanaivo P, Wright CW, Willcox ML, Gilbert B (2011) Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J 10:S4CrossRefPubMedPubMedCentralGoogle Scholar
  79. Redondo-Blanco S, Fernandez J, Gutierrez-del-Rio I, Villar CJ, Lombo F (2017) New insights toward colorectal cancer chemotherapy using natural bioactive compounds. Front Pharmacol 8:109CrossRefPubMedPubMedCentralGoogle Scholar
  80. Rehman MU, Tahir M, Khan AQ, Khan R, Lateef A, Hamiza OO, Qamar W, Ali F, Sultana S (2013) Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-kβ. Toxicol Lett 216:146–158CrossRefPubMedGoogle Scholar
  81. Remesh A (2012) Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol 1:2–12CrossRefGoogle Scholar
  82. Samoylenko A, Hossain JA, Mennerich D, Kellokumpu S, Hiltunen JK, Kietzmann T (2013) Nutritional countermeasures targeting reactive oxygen species in cancer: from mechanisms to biomarkers and clinical evidence. Antioxid Redox Signal 19:2157–2196CrossRefPubMedPubMedCentralGoogle Scholar
  83. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823CrossRefPubMedGoogle Scholar
  84. Sultana N, Ata A (2008) Oleanolic acid and related derivatives as medicinally important compounds. J Enz Inhibit Med Chem 23:739–756CrossRefGoogle Scholar
  85. Swinney DC, Anthony J (2011) How were new medicines discovered. Nat Rev Drug Discov 10:507–519CrossRefPubMedGoogle Scholar
  86. Sznarkowska A, Kostecka A, Meller K, Bielawski KP (2017) Inhibition of cancer antioxidant defense by natural compounds. Oncotarget 8:15996–16016CrossRefPubMedGoogle Scholar
  87. Tsume Y, Incecayir T, Song X, Hilfinger JM, Amidon GL (2014) The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability. Eur J Pharm Biopharm 86:514–523CrossRefPubMedGoogle Scholar
  88. Van DH, Jacobs DI, Snoeijer W, Hallard D, Verpoorte R (2004) The Catharanthus alkaloids: pharmacognosy and biotechnology. Curr Med Chem 11:607–628CrossRefGoogle Scholar
  89. Veeresham C (2012) Natural products derived from plants as a source of drugs. J Adv Pharm Tech Res 3:200–201CrossRefGoogle Scholar
  90. Wink M, Van Wyk BE (2008) Mind-altering and poisonous plants of the world. Timber Press, PortlandGoogle Scholar
  91. Workman P, Collins I (2014) Modern cancer drug discovery: integrating targets, technologies, and treatments for personalized medicine. In: Neidle S (ed) Cancer drug design and discovery, 2nd edn. Academic, San Diego, pp 3–53CrossRefGoogle Scholar
  92. Zhang D, Luo G, Ding X, Lu C (2012) Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B 2:549–561CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Charles Gnanaraj
    • 1
    • 2
  • Sivapragasam Gothai
    • 3
  • Katyakyini Muniandy
    • 3
  • Rengarajan Thamaraiselvan
    • 2
  • Palanisamy Arulselvan
    • 3
    • 4
  1. 1.Biotechnology Research InstituteUniversiti Malaysia Sabah, Jalan UMSKota KinabaluMalaysia
  2. 2.Scigen Research and Innovation, Periyar Technology Business IncubatorThanjavurIndia
  3. 3.Laboratory of Vaccines and Immunotherapeutics, Institute of BioscienceUniversiti Putra MalaysiaSerdangMalaysia
  4. 4.Muthayammal Centre for Advanced Research, Muthayammal College of Arts and ScienceRasipuram, NamakkalIndia

Personalised recommendations